August 1989
Volume 30, Issue 8
Free
Articles  |   August 1989
Prostaglandin F2 alpha effects on intraocular pressure negatively correlate with FP-receptor stimulation.
Author Affiliations
  • D F Woodward
    Allergan, Inc., Discovery Research, Irvine, California 92715.
  • J A Burke
    Allergan, Inc., Discovery Research, Irvine, California 92715.
  • L S Williams
    Allergan, Inc., Discovery Research, Irvine, California 92715.
  • B P Palmer
    Allergan, Inc., Discovery Research, Irvine, California 92715.
  • L A Wheeler
    Allergan, Inc., Discovery Research, Irvine, California 92715.
  • E Woldemussie
    Allergan, Inc., Discovery Research, Irvine, California 92715.
  • G Ruiz
    Allergan, Inc., Discovery Research, Irvine, California 92715.
  • J Chen
    Allergan, Inc., Discovery Research, Irvine, California 92715.
Investigative Ophthalmology & Visual Science August 1989, Vol.30, 1838-1842. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D F Woodward, J A Burke, L S Williams, B P Palmer, L A Wheeler, E Woldemussie, G Ruiz, J Chen; Prostaglandin F2 alpha effects on intraocular pressure negatively correlate with FP-receptor stimulation.. Invest. Ophthalmol. Vis. Sci. 1989;30(8):1838-1842.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

According to the current working classification for prostanoid receptors, the prostaglandin F2 alpha-sensitive receptor (FP-receptor) may be identified by comparing the rank order of activity of prostaglandin F2 alpha (PGF2 alpha) and its analogues. In order to further understand the pharmacology of PGF2 alpha-induced ocular hypotension, the intraocular pressure response to PGF2 alpha and selected analogues was compared with their rank order of activity in typical FP-receptor preparations such as contraction of the cat iris sphincter and affinity for corporal luteal membrane binding sites. The rank order of potency for decreasing intraocular pressure was as follows: PGF2 alpha greater than PGF1 alpha greater than 16-phenoxytetranor PGF2 alpha greater than 17-phenyltrinor PGF2 alpha = fluprostenol (inactive). For cat iris sphincter contraction, the rank order of potency appears to be fluprostenol = 17-phenyltrinor PGF2 alpha greater than 16-phenoxytetranor PGF2 alpha = PGF2 alpha greater than PGF1 alpha. The rank order of potency for PGF2 alpha analogues in decreasing intraocular pressure appears to negatively correlate with the rank order for cat iris sphincter contraction and literature values for corporal luteal membrane binding. It is concluded that the ocular hypotensive effect of PGF2 alpha is not mediated by the FP-receptor.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×